Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Occidental Petroleum Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Occidental Petroleum Corporation trades at $58.99 (market cap $55.89B). The key difference: Occidental Petroleum Corporation is far larger — about 6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Occidental Petroleum Corporation pays a 2% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OXY | |
|---|---|---|
Market Cap | $9.39B | $55.89B |
Sector | Health | Energy |
52-Week High | $354.54 | $66.24 |
52-Week Low | $241.71 | $38.92 |
Enterprise Value | $9.14B | $74.65B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Occidental Petroleum (OXY) trades at $55.91, down 0.23% today, with a bullish technical outlook supported by moving averages and a consensus price target of $69.25. Recent Q2 2026 earnings of $2.40 per share beat expectations, driven by higher oil prices and strong cash flow, while the company focuses on debt reduction and targets over $4 billion in sustainable cash flow by 2030.
OXY presents a buy opportunity with solid profitability and growth prospects, but faces risks from oil price volatility and competitive pressures. Analysts are optimistic, with 50% recommending buy, though investors should monitor execution on cash flow targets and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
